Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Fentanyl
Instanyl
Not routinely available
SMC (579/09)
29/03/2023
Indication
Management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. See link to SMC advice for full details of restriction.
Therapeutic Area
Central nervous system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
50 micrograms/dose, 100 micrograms/dose, 200 micrograms/dose nasal spray
Comments
-